TuHURA Biosciences, Inc. (Nasdaq: HURA), a Tampa, Florida-based clinical-stage immuno-oncology company, announced on October 13, 2026, that the United States Patent and Trademark Office had issued Patent No. 12,760,104 covering its VISTA-targeting antibody programme, TBS-2025. The patent, titled Anti-VISTA Antibodies and Uses Thereof, extends the company’s intellectual property protection beyond the original monoclonal antibody to encompass specified antibody fragments, structural modifications, bispecific and multispecific formats, and potential therapeutic combinations.
TuHURA stated that the patent term extends to February 18, 2042, before any applicable patent term adjustments or regulatory extensions. The claims also address therapeutic methods involving combinations with chemotherapy, radiotherapy, targeted treatments and immune checkpoint inhibitors, as well as potential applications beyond oncology. The development strengthens the legal framework surrounding TBS-2025 but does not constitute clinical validation, drug approval or evidence that any proposed combination treatment is effective.
The patent announcement follows a separate regulatory milestone on September 14, when TuHURA received FDA clearance to investigate TBS-2025 in patients with relapsed or refractory acute myeloid leukemia carrying NPM1 mutations. The planned Phase 1b study will initially evaluate the antibody as monotherapy in patients whose disease has progressed after menin inhibitor treatment. This represents an important shift toward a molecularly defined blood cancer population following earlier human testing in advanced solid tumors.
For TuHURA, the broader patent portfolio may support future drug development and partnering discussions while increasing the range of antibody designs that the company can investigate. However, its commercial significance will depend primarily on whether TBS-2025 demonstrates a clinically meaningful benefit, maintains an acceptable safety profile and progresses through subsequent regulatory development.
What does US Patent 12,760,104 protect within TuHURA’s VISTA antibody programme?
The newly issued patent contains 18 claims and identifies antibody structures designed to bind VISTA, an immune-regulatory protein also known as V-domain immunoglobulin suppressor of T-cell activation. Its scope includes defined antigen-binding regions and associated antibody modifications. TuHURA describes the additional protection as covering specified bispecific and multispecific antibody configurations across human antibody classes.
The patent also addresses methods of using covered antibodies alone or alongside other therapies, including radiotherapy, chemotherapy, tyrosine kinase inhibitors and PD-1-targeted treatments. These combinations are potentially relevant because cancers can evade immune attack through more than one biological pathway. However, patent protection for a proposed combination does not establish that the combination has been clinically tested or shown to improve patient outcomes.
Another important element concerns applications beyond cancer. TuHURA says the claims encompass potential treatment methods involving autoimmune diseases and infections, broadening the range of therapeutic settings contemplated by the intellectual property. The company has not announced completed clinical trials establishing efficacy for TBS-2025 in either category.
The patent record identifies Kineta, Inc. as the assignee associated with the original application, reflecting the programme’s development before TuHURA acquired Kineta in June 2025. The acquisition brought the antibody, previously known as KVA1213, into TuHURA’s portfolio. The new patent therefore expands protection associated with an acquired asset rather than representing an entirely new antibody discovery.
The stated February 2042 patent term offers a potential period of protection extending beyond the expected near-term clinical development timeline. Actual commercial exclusivity, however, will depend on the final patent claims, enforceability, competing rights, regulatory approvals and any applicable extensions. The existence of a granted patent does not guarantee that a medicine will reach the market or face no competition.
Why is TuHURA targeting VISTA in NPM1-mutated acute myeloid leukemia?
Acute myeloid leukemia is an aggressive blood cancer involving the accumulation of abnormal myeloid cells in the bone marrow and bloodstream. These cells can interfere with normal blood formation, contributing to anemia, infections and bleeding complications. Treatment decisions depend on factors including patient fitness, previous therapy and the genetic characteristics of the leukemia.
NPM1 mutations define an important molecular subgroup of AML and influence both disease biology and treatment selection. TuHURA is investigating whether VISTA contributes to immune escape in this population, particularly when leukemia returns or stops responding to treatment. The company’s research has identified a relationship between certain AML molecular characteristics and increased VISTA expression on malignant cells.
VISTA is an immune checkpoint protein expressed prominently on several myeloid cell populations, including myeloid-derived suppressor cells, as well as on resting T cells. Its biological activity can influence immune responses within the tumor environment. Blocking the pathway may offer a way to modify immune suppression, although the effects of VISTA inhibition can differ between diseases and biological settings.
TuHURA has reported preclinical findings suggesting that suppressing VISTA activity can improve antileukemia immune responses in experimental models. The company has also described animal studies in which VISTA-targeted interventions were associated with longer survival. These results provide a scientific rationale for human testing but do not establish that patients will experience comparable benefits.
The planned trial will examine a population in which the disease has already proved difficult to control. That focus gives TBS-2025 a specific clinical question: whether VISTA inhibition can produce meaningful antileukemia activity after an established molecular treatment has failed.
How does TBS-2025 fit alongside newly approved menin inhibitors for AML?
The treatment landscape for NPM1-mutated AML changed in 2025 with FDA approvals for two menin inhibitors. In October 2025, the agency approved Syndax Pharmaceuticals’ revumenib for eligible adults and children aged at least one year with relapsed or refractory NPM1-mutated AML who lack satisfactory alternative treatments. The following month, it approved Kura Oncology’s ziftomenib for eligible adults with relapsed or refractory disease carrying a susceptible NPM1 mutation.
These medicines target biological processes associated with certain leukemia-driving genetic alterations and provide treatment options for patients who previously had limited alternatives. Nevertheless, responses are not universal, and patients can experience recurrent disease after an initial benefit. This creates a rationale for investigating additional mechanisms, including approaches intended to alter immune recognition of malignant cells.
TuHURA initially discussed combining TBS-2025 with menin inhibitors as part of its broader development strategy. The September FDA clearance, however, specifically permits a Phase 1b investigation beginning with TBS-2025 monotherapy in patients who have failed or relapsed following menin inhibitor treatment. Future combination development should therefore be distinguished from the currently described initial clinical investigation.
The difference is clinically significant because demonstrating activity after a menin inhibitor has failed would address a different treatment question from adding VISTA inhibition to a menin inhibitor before resistance develops. The initial approach may help investigators identify an appropriate dose and evaluate whether the antibody produces measurable activity in a heavily pretreated population. It cannot, by itself, establish that the combination of two therapies is more effective than either agent alone.
If early results prove encouraging, TuHURA has indicated that it may discuss additional dose optimization and development opportunities with the FDA. Any possible accelerated approval strategy would remain contingent on the strength of the clinical evidence and regulatory agreement.
What does the earlier 40-patient TBS-2025 trial establish about human safety?
Before TuHURA acquired Kineta, the antibody was evaluated in an early-phase clinical programme involving patients with relapsed or refractory advanced solid tumors. TuHURA reports that 24 participants received antibody monotherapy and another 16 received the medicine in combination with pembrolizumab. This provides previous human exposure data relevant to the selection of doses and safety monitoring for future studies.
The company reported that TBS-2025 was administered every two weeks at doses up to 1,000 mg with an acceptable observed tolerability profile in the investigated groups. Pharmacokinetic and pharmacodynamic findings indicated greater than 90% VISTA receptor occupancy throughout the two-week dosing interval. Those measurements support evidence that the antibody interacted with its intended molecular target at the evaluated doses.
However, receptor occupancy is a pharmacological observation rather than a clinical efficacy endpoint. Demonstrating that an antibody binds a target does not establish that patients experience tumor regression, longer survival or improvement in symptoms. Likewise, tolerability among 40 patients with advanced solid tumors cannot establish the safety of the treatment in AML, where patients may have substantially different blood counts, immune function and complications.
The earlier trial also involved a heterogeneous population rather than patients selected specifically for NPM1 mutations or resistance to menin inhibitors. Its principal contribution to the current programme is therefore experience with human dosing and biological activity. The new AML investigation must generate disease-specific evidence.
How does the new patent fit into TuHURA’s wider immuno-oncology strategy?
TuHURA is developing several approaches intended to address different forms of resistance to cancer immunotherapy. Its lead programme, IFx-2.0, is an innate immune agonist being investigated in a randomized Phase 3 trial as an adjunct to pembrolizumab in advanced or metastatic Merkel cell carcinoma. That programme differs from TBS-2025 in both its mechanism and clinical development stage.
The company is also exploring antibody-drug conjugate designs targeting immune-suppressive myeloid-derived suppressor cells. These research programmes use a different platform involving delta opioid receptor-related technology. Their objective is to interfere with mechanisms that may prevent immune cells from mounting effective antitumor responses.
The expanded TBS-2025 patent adds intellectual property around another component of this broader strategy. By including specified bispecific and multispecific formats, it may provide flexibility for future molecules combining VISTA binding with another targeted function. Such possibilities remain at the level of protected designs or future development concepts unless supported by actual experimental and clinical results.
The patent could also be relevant to potential pharmaceutical partnerships. Companies considering licensing or jointly developing an experimental medicine typically evaluate the durability and scope of patent protection alongside scientific evidence, manufacturing requirements and commercial prospects. Broad intellectual property coverage can strengthen negotiating options, but no new TBS-2025 licensing or collaboration agreement was announced on October 13.
What does TuHURA’s financial position mean for continued VISTA development?
TuHURA’s second-quarter 2026 financial statements showed approximately $1 million in cash and cash equivalents at June 30. The company also reported access to financing arrangements, including a credit facility announced in April, and subsequent proceeds from that arrangement. Those sources of potential funding are important because clinical development costs can rise as programmes move from small early-phase investigations into larger studies.
A patent grant does not produce cash by itself and should not be equated with additional financing. Its potential financial benefits would arise indirectly through licensing, partnerships, strengthened asset valuation or eventual commercialization. None of those outcomes is guaranteed by the October announcement.
The company’s research and development expenditure reached approximately $6.6 million during the second quarter of 2026, reflecting increased clinical development activity. Maintaining progress across the IFx-2.0 programme, TBS-2025 and additional antibody research creates competing demands for capital. Investors therefore need to assess the patent within the wider context of funding requirements and clinical execution.
For the publicly listed company, the most important evidence of progress will come from the commencement of the AML study, enrollment, dose optimization and patient outcomes. The issued patent may protect potential value, but clinical results will determine whether that value has a realistic path toward commercialization.
What milestones will determine whether the TBS-2025 patent becomes commercially valuable?
The immediate priority is advancing the FDA-cleared Phase 1b AML study and establishing an appropriate dose for further investigation. Investigators will need to characterize adverse events, pharmacokinetics, biological activity and any evidence of leukemia response. The enrolled population’s previous treatment history will be particularly important when interpreting whether observed activity addresses resistance after menin inhibitor therapy.
Subsequent development could explore whether VISTA expression helps identify patients more likely to benefit. However, the presence of a biological target does not automatically make it a validated predictive biomarker. Establishing that relationship would require systematic measurement and clinical correlation.
The patent’s wider therapeutic and molecular scope may offer flexibility over the longer term, including development of new antibody configurations. But expanding into other hematologic cancers, autoimmune disease or infections would require separate scientific evidence and an appropriate regulatory programme. Patent coverage should not be confused with proof that the same mechanism will be useful in every listed condition.
TuHURA’s October patent award reinforces the intellectual property position surrounding an acquired immunotherapy asset at a time when the company is redirecting clinical development toward a defined AML population. Its commercial significance lies in protecting potential future treatments rather than demonstrating a new therapeutic benefit. The decisive test will be whether TBS-2025 can produce reproducible antileukemia activity with acceptable safety after menin inhibitor failure, providing the clinical foundation needed to justify further investment and development.
